Multi-Leu PACE4 inhibitor retention within cells is PACE4 dependent and a prerequisite for antiproliferative activity

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Couture, Frédéric ^a,b   Ly, Kévin ^a,b   Levesque, Christine ^a,b   Kwiatkowska, Anna ^a,b   Ait Mohand, Samia ^b,c   Desjardins, Roxane ^a,b   Guérin, Brigitte ^a,b   Day, Robert ^a,c  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LEUCINE; PROPROTEIN CONVERTASE 4; PROPROTEIN CONVERTASE 4 INHIBITOR; SERINE PROTEINASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PCSK6 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CONTROLLED STUDY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; MOUSE; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; MICE; NEOPLASMS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934977276     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/824014     Document Type: Article

References (32)

1. B. J. Feldman and D. Feldman, "The development of and rogenindependent prostate cancer, " Nature Reviews Cancer, vol. 1, no. 1, pp. 34-45, 2001.
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014, " CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
3. J. L. Chen, J. Li, W. M. Stadler, and Y. A. Lussier, "Proteinnetwork modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence, " Journal of the American Medical Informatics Association, vol. 18, no. 4, pp. 392-402, 2011.
4. P. J. Russell, S. Bennett, and P. Stricker, "Growth factor involvement in progression of prostate cancer, " Clinical Chemistry, vol. 44, no. 4, pp. 705-723, 1998.
5. N.G. Seidah and A. Prat, "Thebiology and therapeutic targeting of the proprotein convertases, " Nature Reviews Drug Discovery, vol. 11, no. 5, pp. 367-383, 2012.
6. F. Couture, F. DAnjou, and R. Day, "On the cutting edge of proprotein convertase pharmacology: frommolecular concepts to clinical applications, " BioMolecular Concepts, vol. 2, no. 5, pp. 421-438, 2011.
7. F. DAnjou, S. Routhier, J.-P. Perreault et al., "Molecular validation of pace4 as a target in prostate cancer, " Translational Oncology, vol. 4, no. 3, pp. 157-172, 2011.
8. S. Kang, Y. Zhao, K. Hu et al., "miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway, " The Prostate, vol. 74, no. 11, pp. 1095-1106, 2014.
9. F. Couture, F. DAnjou, R. Desjardins, F. Boudreau, and R. Day, "Role of proprotein convertases in prostate cancer progression, " Neoplasia, vol. 14, no. 11, pp. 1032-1042, 2012.
10. R. Longuespee, F. Couture, C. Levesque et al., "Implications of proprotein convertases in ovarian cancer cell proliferation and tumor progression: insights for PACE4 as a therapeutic target, " Translational Oncology, 2014.
11. C. Levesque, M. Fugere, A. Kwiatkowska et al., "The multileu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells, " Journal of Medicinal Chemistry, vol. 55, no. 23, pp. 10501-10511, 2012.
12. F. Couture, C. Levesque, V. Dumulon-Perreault et al., "PACE4-based molecular targeting of prostate cancer using an engineered 64Cu-radiolabeled peptide inhibitor, " Neoplasia, vol. 16, no. 8, pp. 634-643, 2014.
13. F. DAnjou, F. Couture, R. Desjardins, and R. Day, "Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells, "Methods inMolecular Biology, vol. 1103, pp. 67-82, 2014.
14. S. K. Zeisler, R. A. Pavan, J. Orzechowski, R. Langlois, S. Rodrigue, and J. E. van Lier, "Production of 64Cu on the sherbrooke TR-PET cyclotron, " Journal of Radioanalytical and Nuclear Chemistry, vol. 257, no. 1, pp. 175-177, 2003.
15. P. Fournier, V. Dumulon-Perreault, S. Ait-Moh and et al., "Comparative study of 64Cu/NOTA-[D-Tyr6, betaAla11, Thi13, Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging, " EJNMMI Research, vol. 2, p. 8, 2012.
16. A. Kwiatkowska, F. Couture, C. Levesque et al., "Design, synthesis, and structure-Activity relationship studies of a potent PACE4 inhibitor, " Journal of Medicinal Chemistry, vol. 57, no. 1, pp. 98-109, 2014.
17. A. Tsuji, S. Yoshida, S.-I. Hasegawa et al., "Human subtilisin-like proprotein convertase, PACE4 (SPC4) gene expression is highly regulated through E-box elements in HepG2 and GH4C1 cells, " Journal of Biochemistry, vol. 126, no. 3, pp. 494-502, 1999.
18. N. G. Seidah, M. Chretien, and R. Day, "The family of subtilisin/ kexin like pro-protein and pro-hormone convertases: divergent or shared functions, " Biochimie, vol. 76, no. 3-4, pp. 197-209, 1994.
19. K. Yuasa, K. Suzue, M. Nagahama, Y. Matsuda, and A. Tsuji, "Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: possible role of E2F-mediated upregulation of PACE4 in tumor progression, " Gene, vol. 402, no. 1-2, pp. 103-110, 2007.
20. S. Ait-Moh and , P. Fournier, V. Dumulon-Perreault et al., "Evaluation of 64Cu-labeled bifunctional Chelate-Bombesin conjugates, " Bioconjugate Chemistry, vol. 22, no. 8, pp. 1729-1735, 2011.
21. G. I. Evan and K. H. Vousden, "Proliferation, cell cycle and apoptosis in cancer, " Nature, vol. 411, no. 6835, pp. 342-348, 2001.
22. N. C. Harris and M. G. Achen, "The proteolytic activation of angiogenic and lymphangiogenic growth factors in cancer-its potential relevance for therapeutics and diagnostics, " Current Medicinal Chemistry, vol. 21, no. 16, pp. 1821-1842, 2014.
23. D. B. Rifkin, R. Mazzieri, J. S. Munger, I. Noguera, and J. Sung, "Proteolytic control of growth factor availability, " APMIS, vol. 107, no. 1, pp. 80-85, 1999.
24. B. Turk, "Targeting proteases: successes, failures and future prospects, " Nature ReviewsDrugDiscovery, vol. 5, no.9, pp. 785-799, 2006.
25. R. A. Bok, E. J. Hansell, T. P. Nguyen, N. M. Greenberg, J. H. McKerrow, and M.A. Shuman, "Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model, " Prostate Cancer and Prostatic Diseases, vol. 6, no. 4, pp. 272-280, 2003.
26. M. Egeblad and Z. Werb, "New functions for the matrix metalloproteinases in cancer progression, " Nature Reviews Cancer, vol. 2, no. 3, pp. 161-174, 2002.
27. A.-M. Khatib, G. Siegfried, M. Chretien, P. Metrakos, and N. G. Seidah, "Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy, " American Journal of Pathology, vol. 160, no. 6, pp. 1921-1935, 2002.
28. D. E. Bassi, J. Zhang, J. Cenna, S. Litwin, E. Cukierman, and A. J. P. Klein-Szanto, "Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis, " Neoplasia, vol. 12, no. 7, pp. 516-526, 2010.
29. R. E. Page, A. J. P. Klein-Szanto, S. Litwin et al., "Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer, " Cellular Oncology, vol. 29, no. 4, pp. 289-299, 2007.
30. N. A. Taylor, W. J. M. van de Ven, and J. W. M. Creemers, "Curbing activation: proprotein convertases in homeostasis and pathology, " The FASEB Journal, vol. 17, no. 10, pp. 1215-1227, 2003.
31. M. Lindgren, M.Hällbrink, A. Prochiantz, and U. Langel, "Cellpenetrating peptides, " Trends in Pharmacological Sciences, vol. 21, no. 3, pp. 99-103, 2000.
32. F. Madani, S. Lindberg, U. Langel, S. Futaki, and A. Gräslund, "Mechanisms of cellular uptake of cell-penetrating peptides, " Journal of Biophysics, vol. 2011, Article ID 414729, 10 pages, 2011.